Skip to content
Home » Vaccines » COVID-19 vaccine » Page 4

COVID-19 vaccine

COVID vaccine diabetes

COVID vaccine reduces the risk of post-infection diabetes

Research indicates a potential link between COVID-19 infection and an increased risk of type 2 diabetes, with the COVID-19 vaccine shown to reduce this risk. Studies suggest that vaccinated individuals have a significantly lower likelihood of developing diabetes after a COVID-19 infection compared to unvaccinated individuals. This underscores the importance of getting vaccinated to mitigate the risk of diabetes.

turbo cancer

COVID-19 vaccines do not cause turbo cancer

In the era of misinformation, the claim that COVID-19 vaccines cause “turbo cancer” is unsupported by scientific evidence and is likely a myth perpetuated by anti-vaccine proponents. COVID-19 vaccines are extensively tested, safe, and vital in combating the COVID-19 pandemic, particularly for at-risk individuals like those with cancer (Approx. 83 words).

JN.1 COVID variant

JN.1 variant of COVID update

The JN.1 COVID-19 variant, a subvariant of Omicron, is rapidly spreading in the USA. While it may evade immunity from vaccines or previous infection, current vaccines appear effective against it. It poses a greater risk to the unvaccinated. Public health agencies are closely monitoring its transmission and severity to prevent potential disasters. COVID-19 remains a significant threat.

woman lying on bed while blowing her nose

COVID vaccines may prevent long COVID conditions

Recent research compared COVID-19 vaccine recipients with unvaccinated individuals who had breakthrough infections, showing significantly lower risks of long-term health issues in the vaccinated group. Long-COVID symptoms, including hypertension, diabetes, and heart disease, were reduced by 65-79% in the vaccinated group after 90 days, indicating the vaccine’s long-term benefits.


Florida Surgeon General Ladapo is wrong about COVID vaccines

Florida’s Surgeon General, Joseph Ladapo, alleged that COVID-19 vaccines might contain SV40 virus DNA, without evidence. FDA’s Dr. Peter Marks strongly refuted Ladapo’s claims based on scientific evidence, noting Ladapo’s history of spreading vaccine misinformation. This article reviews Ladapo’s unfounded statements and highlights their lack of scientific merit.

myocarditis COVID-19 vaccines

Myocarditis and COVID vaccines – what are the facts?

While myocarditis, a rare inflammation of the heart often caused by viruses, has been linked to COVID-19 vaccines, the risk is negligible. Most cases occur in young men after multiple doses and resolve within 90 days without serious harm. The risk of getting myocarditis from a COVID-19 vaccine is significantly lower than the risk of myocarditis from the disease itself. Despite fears, there are no recorded deaths due to myocarditis post-vaccination.

rsv COVID flu tripledemic

Flu, COVID, RSV on the rise — beware the tripledemic

The USA, including California, faces a ‘tripledemic’ of seasonal flu, new COVID-19 variants, and respiratory syncytial virus (RSV). All three respiratory viruses, particularly harmful to seniors and children, can be prevented through vaccination. Despite this, many places are reporting low vaccination rates, especially among older people. The content highlights RSV’s severity and contagion, recent research into the virus, and the situation with the three diseases in California and other states.


New JN.1 COVID variant may become a concern

The COVID-19 variant JN.1, a descendent lineage of Omicron subvariant BA.2.86, is causing public health concerns although there is no current evidence of increased risk. The CDC is closely monitoring this variant, comprising 15-29% of US COVID-19 cases. Preliminary research indicates existing vaccines may protect against JN.1. However, the effect on immunity from natural infection is unknown.

BA.2.86 variant

New information on the BA.2.86 COVID variant

The BA.2.86 variant of the SARS-CoV-2 virus, also called the Pirola variant, is back on the CDC’s radar despite not causing significant infection increases previously. It may evade vaccines or natural immunity and is currently accounting for 9% of cases but isn’t driving infection or hospitalization increases. The public health risk is considered low compared to other variants. Vaccinated individuals have reduced risk of hospitalization, and there is no evidence the strain can evade vaccine or natural immunity entirely. Updates will continue as the situation develops.